psoriatic%20arthritis
PSORIATIC ARTHRITIS
Psoriatic arthritis is a chronic inflammatory arthropathy associated with cutaneous psoriasis.
It is a progressive disease with asymmetric joint distribution pattern and rheumatoid factor is negative.
It can develop at any time including childhood but most often occurs between 30-50 years old.
Symptoms may range from mild to very severe.

Psoriatic Arthritis Drug Information

Drug Information

Indication: Acute & chronic treatment of signs & symptoms of OA & RA; ankylosing spondylitis (AS); acute gouty...

Indication: Management of acute pain in adults & treatment of primary dysmenorrhea. Relief of acute & chronic pain...

Indication: Signs & symptoms & inhibiting the progression of structural damage in moderately to severely active rh...

Indication: OA, RA, ankylosing spondylitis.

Indication: RA; ankylosing spondylitis; psoriatic arthritis; psoriasis; Crohn's & fistulizing Crohn's disease; ulcerat...

Indication: In combination w/ methotrexate (MTX) for moderate to severe active RA in adults when response to disease-modif...

Indication: Symptomatic treatment of OA (arthrosis, degenerative joint disease), RA & ankylosing spondylitis.

Indication: Inflammatory & degenerative forms of rheumatism: RA, juvenile RA, ankylosing spondylitis, OA & spondyl...

Indication: Relief of fever associated w/ cold & flu, pain eg, teething, toothache, earache, sore throat, headache, mi...

Indication: Relief of fever & mild to moderate pain including headache, dental pain, post-op pain, dysmenorrhoea; musc...

1  /  12
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Rheumatology digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 6 days ago
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Pearl Toh, 21 Sep 2020
Early and sustained treatments with simplified regimen are the key to achieving good asthma control, said experts during a presentation at the ERS 2020 Congress.
2 days ago
Nocturia is a risk factor for mortality, according to the results of the Nagahama Study, which boasts of a low incidence of missing data and high representation of the general population.
Audrey Abella, 14 Oct 2020
Despite a 90-percent cure rate after first treatment for children with acute lymphoblastic leukaemia (ALL), approximately 10–15 percent of patients with paediatric ALL will experience relapse. [Expert Rev Anticancer Ther 2017;17:725-736] A recent webinar on the current landscape of ALL highlighted the potential of immunotherapy for paediatric patients with relapsed or refractory ALL, thus providing hope for this high-risk patient group.